BIRLA INSTITUTE OF TECHNOLOGY, MESRA, RANCHI (END SEMESTER EXAMINATION)

CLASS: M. Pharm. BRANCH: PHARMACY SUBJECT: MQA104T PRODUCT DEVELOPMENT & TECHNOLOGY TRANSI		SEMESTER: 1st SESSION: SP/2022 FFR	
TIME: 3.00 Hours INSTRUCTIONS:		FULL MARK: 75	
 The missing data, if any, may be assumed suitably. Before attempting the question paper, be sure that you have got the correct question paper. Tables/Data hand book/Graph paper etc. to be supplied to the candidates in the examination hall. Answer any five questions. 			
1a.	What do you mean by drug discovery? Discuss the various aspects need to be considered for designi clinical trials. (CO1) Describe the composition and role of investigation new drug (IND) application review team. (CO1)		[7]
1b.			[8]
2a.	What are various ingredients present in content and format of IND application. Discuss any three ingredients in detail. (CO1) What do you mean by preformulation studies? Discuss any three aspects of preformulation studies in detail. (CO2)		[7]
2b.			[8]
3a. 3b.	Describe how solubility of weak base is affected by pH using suitable equation. (CO3) Describe how solubility of weak acid is affected by pH using suitable equation. (CO3)		[7] [8]
4a. 4b.	Discuss in detail technology transfer checklist. (CO2) Elaborate on importance of technology contract and terms associated with contract.	(CO2)	[7] [8]
5a. 5b.	Discuss briefly steps in pilot plant scale up. (CO1) Explain in short and draw layout for pilot plant scale up for solid dosage formula (CO3)	tions as per GMP.	[7] [8]
6a. 6b.	Discuss about significance and path of pilot plant scale up. (CO1) Describe about technology transfer documentation using a case study. (CO2)		[7] [8]
7a. 7b.	Elaborate on analytical method transfer in technology transfer. (CO2) Explain in detail SUPAC. (CO3)		[7] [8]

:::::24/11/2022::::E